Latest News and Press Releases

OTraces awarded $2 Million Florida Department of Health grant to validate its proteomic blood test to reduce unnecessary prostate biopsies.

Annals of Internal Medicine publishes study showing potential benefits of Stockholm3 in identifying patients with aggressive prostate cancer.

FocalTherics™ Expands Access to Focal One® Robotic HIFU for Veterans with Prostate Cancer through Agreement with MellingMedical AUSTIN, Texas, June 16, 2026 (GLOBE NEWSWIRE) -- FocalTherics...

Completion of patient dosing in the registrational Phase 2 clinical trial for 64Cu-PSMA-I&T - a PET radiopharmaceutical targeting prostate-specific membrane antigen (PSMA) expressed on prostate...

Alpha Tau and Tolmar Announce Strategic Collaboration to Bring Alpha DaRT® Therapy to U.S. Urological Cancer Patients

NEEDHAM, Mass., June 01, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal...

Curium’s strategic investment of over €32 million will establish a European production line for 177Lu-PSMA-I&T, a therapeutic agent for patients with metastatic castration-resistant prostate...

EDAP Announces Corporate Name Change to FocalTherics™ to Reflect Exclusive Focus on High-Growth Robotic Focal Therapy Company will Begin Trading Under New Ticker Symbol “FOCL” at Market Open on June...

NUCLIDIUM announced a CHF 26.4 million extension led by existing investors to accelerate clinical development of NU101 and NU201 radiotheranostic programs.

Myriad Genetics Launches Prolaris® + AI, the First Prostate Cancer Test to Combine Genomics and Digital Pathology Artificial Intelligence